Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid residues are negatively charged, nine-carbon monosaccharides most commonly found as terminal modifications on glycoproteins and glycolipids on the outer surface of vertebrate cell membranes[1][2]. These residues play diverse roles including mediating cell-cell recognition, stabilizing glycoprotein structure, regulating immune responses (such as complement pathway and Siglec interactions), supporting neural development, and modulating cell adhesion[2][3][5]. Pathogens—including viruses (e.g., influenza), bacteria, and protozoa—exploit sialic acid residues to bind and invade host cells, often contributing to infection and immune evasion, a phenomenon called molecular mimicry[3][4][6]. Sialylation levels on the cell surface dynamically affect physiological processes such as inflammation, neuronal signaling, and cancer metastasis by altering cell repellency, immune cell trafficking, and masking of antigenic sites[1][2][3][4]. However, "host cell surface sialic acid residues" describes a common cell surface feature (a chemical modification), not a discrete protein or conventional therapeutic target, rendering direct drug targeting inappropriate and likely unsafe[2][4]. Summary: - "Host cell surface sialic acid residues" refers to a common terminal sugar modification, not a canonical receptor, protein, or established therapeutic target. - Many pathogens exploit these glycans for host entry but drugs do not directly target these residues because of their ubiquity and essential cellular functions. - Sialylation patterns in disease may serve as biomarkers, especially for cancer and infection. - Targeting strategies focus on blocking pathogen interaction or modulating related signaling pathways, not on the residues themselves.
Not applicable for traditional drug targeting; most interest is in the mechanism of viral or microbial attachment (e.g., influenza hemagglutinin binds α2,6- or α2,3-linked sialic acid for entry)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid residue (host cell surface).